Implantable neurostimulator-implemented method for managing bradycardia through vagus nerve stimulation
A method for managing bradycardia through vagus nerve stimulation is provided. An implantable neurostimulator configured to deliver electrical therapeutic stimulation in both afferent and efferent directions of a patient's cervical vagus nerve is provided. An operating mode is stored, which includes parametrically defining a maintenance dose of the electrical therapeutic stimulation tuned to restore cardiac autonomic balance through continuously-cycling, intermittent and periodic electrical pulses. The maintenance dose is delivered via a pulse generator through a pair of helical electrodes via an electrically coupled nerve stimulation therapy lead independent of cardiac cycle. The patient's physiology is monitored, and upon sensing a condition indicative of bradycardia, the delivery of the maintenance dose is suspended. A progressively increasing amount of time is spent waiting via a controller and, upon sensing a condition indicative of an absence or termination of the bradycardia, a progressively increasing partial maintenance dose is delivered via the pulse generator.
1. A method for managing bradycardia, comprising the steps of:
defining a dose of electrical therapeutic stimulation having a full duty cycle;
delivering the dose to a vagus nerve of a patient;
monitoring the patient's physiology via a physiological sensor;
upon sensing a condition indicative of bradycardia, suspending the delivery of the dose to the vagus nerve, comprising:
initiating a delay;
upon expiry of the delay, checking the patient's physiology via the physiological sensor; and
upon sensing, subsequent to the delay, a condition indicative of an absence or termination of the bradycardia, delivering the dose at a partial duty cycle to the vagus nerve, the partial duty cycle being less than the full duty cycle;
upon sensing, subsequent to delivering the dose at the partial duty cycle, a condition indicative of a continued absence of bradycardia, gradually increasing the duty cycle of the dose to the full duty cycle in response to determining, based on the monitored patient's physiology, that there is a normal sinus rhythm.
2. A method according to claim 1 , wherein the duty cycle is gradually increased while continually monitoring the patient's physiology until a maximum duty cycle is reached.
3. A method according to claim 1 , wherein the delay comprises an amount of time that increases over each previous delay.
4. A method according to claim 1 , further comprising the steps of:
upon sensing a condition indicative of a recurrence of the bradycardia, re-suspending the delivery of the dose to the vagus nerve, comprising:
increasing the delay over a delay most recently used during suspension of the delivery of the dose to the vagus nerve; and
upon expiry of the increased delay, checking the patient's physiology via the physiological sensor.
5. A method according to claim 4 , further comprising the steps of
continuing the re-suspension of the delivery of the dose; and
terminating the delivery of the dose to the vagus nerve once a maximum delay has been reached.
6. A method according to claim 1 , further comprising the step of:
sensing the condition indicative of bradycardia based on at least one of abnormal sinus rhythm and heart rate falling below a threshold.
7. A method according to claim 1 , wherein the duty cycle is in a range of 2% to 89%.
8. A method according to claim 7 , wherein the duty cycle is in a preferred range of 4% to 36%.
9. A method for managing bradycardia, comprising the steps of:
defining a dose of electrical therapeutic stimulation, wherein the electrical therapeutic stimulation comprises a pulsed electrical signal comprising:
a signal ON time;
a signal OFF time;
an output current;
a signal frequency;
a pulse width; and
a duty cycle defined by dividing the signal ON time by the sum of the signal ON time and signal OFF time, the duty cycle of the defined dose being a full duty cycle;
delivering the dose to a vagus nerve of a patient;
monitoring the patient's physiology via a physiological sensor;
upon sensing a condition indicative of bradycardia, suspending the delivery of the dose to the vagus nerve, comprising:
initiating a delay;
upon expiry of the delay, checking the patient's physiology via the physiological sensor; and
upon sensing, subsequent to the delay, a condition indicative of an absence or termination of the bradycardia, delivering the dose at a partial duty cycle to the vagus nerve, the partial duty cycle being less than the full duty cycle;
upon sensing, subsequent to delivering the dose at the partial duty cycle, a condition indicative of a continued absence of bradycardia, gradually increasing the duty cycle of the dose to the full duty cycle in response to determining, based on the monitored patient's physiology, that there is a normal sinus rhythm.
10. A method according to claim 9 , wherein the duty cycle is gradually increased while continually monitoring the patient's physiology until a maximum duty cycle is reached.
11. A method according to claim 9 , wherein the delay comprises an amount of time that increases over each previous delay.
12. A method according to claim 9 , further comprising the steps of:
upon sensing a condition indicative of a recurrence of the bradycardia, re-suspending the delivery of the maintenance dose to the vagus nerve, comprising:
increasing the delay over a delay most recently used during suspension of the delivery of the dose to the vagus nerve; and
upon expiry of the increased delay, checking the patient's physiology via the physiological sensor.
13. A method according to claim 12 , further comprising the steps of:
continuing the re-suspension of the delivery of the dose; and
terminating the delivery of the dose to the vagus nerve once a maximum delay has been reached.
14. A method according to claim 9 , further comprising the step of:
sensing the condition indicative of bradycardia based on at least one of abnormal sinus rhythm and heart rate falling below a minimum threshold.
15. A method according to claim 9 , wherein the pulsed electrical signal further comprises a signal ramp-down time.
16. A method according to claim 9 , wherein the pulsed electrical signal further comprises a signal ramp-up time.
17. A method according to claim 9 , wherein the pulsed electrical signals propagate in both an efferent and afferent direction.
18. A method according to claim 9 , wherein the duty cycle is in a range of 2% to 89%.
19. A method according to claim 18 , wherein the duty cycle is in a preferred range of 4% to 36%.
20. A non-transitory computer readable storage medium storing code for executing by a processor, the processor configured to perform the steps of:
defining a dose of electrical therapeutic stimulation having a full duty cycle;
delivering the dose to a vagus nerve of a patient;
monitoring the patient's physiology via a physiological sensor;
upon sensing a condition indicative of bradycardia, suspending the delivery of the dose to the vagus nerve, comprising:
initiating a delay;
upon expiry of the delay, checking the patient's physiology via the physiological sensor; and
upon sensing, subsequent to the delay, a condition indicative of an absence or termination of the bradycardia, delivering the dose at a partial duty cycle to the vagus nerve, the partial duty cycle being less than the full duty cycle;
upon sensing, subsequent to delivering the dose at the partial duty cycle, a condition indicative of a continued absence of bradycardia, gradually increasing the duty cycle of the dose to the full duty cycle in response to determining, based on the monitored patient's physiology, that there is a normal sinus rhythm.